# CORRESPONDENCE

**Circulating long non-coding RNAs detection** after heart transplantation and its accuracy

in the diagnosis of acute cardiac rejection

Lorena Pérez-Carrillo<sup>1,2</sup>, Isaac Giménez-Escamilla<sup>1,2</sup>, Irene González-Torrent<sup>1</sup>, Marta Delgado-Arija<sup>1,2</sup>, Ignacio Sánchez-Lázaro<sup>1,2,3</sup>, María García-Manzanares<sup>2,4</sup>, Luis Martínez-Dolz<sup>1,2,3</sup>, Manuel Portolés<sup>1,2</sup>, Estefanía Tarazón<sup>1,2\*†</sup> and Esther Roselló-Lletí<sup>1,2\*†</sup>

## Abstract

Long non-coding RNAs (IncRNAs) are closely implicated in biological processes and diseases with high inflammatory components. These molecules exhibit significant temporal and tissue specificity. However, the expression and function of IncRNAs have not been studied in patients after heart transplantation. Thus, we aimed to identify circulating IncRNAs in these patients and evaluate their diagnostic capacity as potential biomarkers for the non-invasive detection of acute cellular rejection (ACR). For them, we performed a transcriptomic study based on ncRNA-seg technology to detect IncRNAs in serum samples, matched to routine endomyocardial biopsies, from patients without rejection episode (0R, n = 12) and with mild (1R, n = 16) or moderate-severe ( $\geq 2R$ , n = 12) ACR. We identified 11,062 circulating IncRNAs in the serum of patients after heart transplantation. Moreover, 6 IncRNAs showed statistically significant expression when the different ACR grades were compared. Among them, AC008105.3, AC006525.1, AC011455.8, AL359220.1, and AC025279.1 had relevant diagnostic capacity for detection of  $\geq$  2R (AUC of 0.850 to 1.000) and 1R (AUC of 0.750 to 0.854) grades, along with high specificity and positive predictive values (≥83%). In addition, AL359220.1 and AC025279.1 were independent predictors for the presence of moderate-severe ACR (odds ratio = 31.132, p < 0.01 and C statistic = 0.939, p < 0.0001; odds ratio = 18.693, p < 0.05and C statistic=0.902, p<0.001; respectively). In conclusion, we describe, for the first time, circulating IncRNAs after heart transplantation as potential candidates for non-invasive detection of ACR. AL359220.1 and AC025279.1 showed excellent diagnostic capability correlating with the severity episode and were strong independent predictors of rejection.

Keywords Acute cellular rejection, Biomarkers, Diagnostic, IncRNAs, Transplantation

<sup>†</sup>Estefanía Tarazón and Esther Roselló-Lletí contributed equally to the study.

\*Correspondence: Estefanía Tarazón Esther Roselló-Lletí esther rosello@iislafe.es

> © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>1</sup>Clinical and Translational Research in Cardiology Unit, Health Research

<sup>4</sup>Department of Animal Medicine and Surgery, Veterinary Faculty, CEU

<sup>3</sup>Heart Failure and Transplantation Unit, Cardiology Department,

University and Polytechnic La Fe Hospital, Valencia, Spain

Institute Hospital La Fe (IISLaFe), Valencia, Spain

Cardenal Herrera University, Valencia, Spain

<sup>2</sup>CIBERCV, Madrid, Spain







## To the editor

Heart transplantation remains the definitive treatment for patients with advanced heart failure or congenital heart disease [1]. Cardiac allograft transplantation is associated with a significant risk of rejection [2], and one of the main events is acute cellular rejection (ACR) [3]. The endomyocardial biopsy (EMB) screening is the gold standard technique for diagnosing cardiac rejection despite its technical limitations and risk to patients [4]. Therefore, alternatives such as liquid biopsy are an interesting source of non-invasive information for the follow-up of heart transplant patients. In recent decades, research has focused on studying genes that code for proteins as potential circulating biomarkers for cardiac rejection [5, 6]. However, protein-coding genes represent less than 2% of the total genome, and more than 90% of the genome is transcribed into non-coding RNAs (ncRNAs). Recent investigations are beginning to include long non-coding RNAs (lncRNAs) as critical molecules in the development of cardiovascular diseases, being proposed as biomarkers and therapeutic targets [7]. In addition, animal studies have indicated alterations in several lncRNAs, which might be related to ACR episodes [8].

Thus, we performed a ncRNA-sequencing study (Supplementary material) to identify the presence of IncRNAs in 40 consecutive serum samples matched to routine EMB from heart transplant patients diagnosed for ACR (grade 0R ACR, n=12; grade 1R ACR, n=16; and grade  $\geq 2R$  ACR, n=12) (Table S1). Specifically, 11,062 circulating lncRNAs were detected. Next, we established a series of criteria for selecting the lncRNAs with the most significant potential as possible biomarkers of ACR, obtaining 57 lncRNAs candidates (Fig. 1A). These showed two divergent lncRNA expression profiles, indicating a clear distinction between  $\geq 2R$  and 0Rgrades. (Fig. 1B). Six of these lncRNAs (AC008105.3, AC006525.1, AC011455.8, AL359220.1, AC025279.1, and HAGLR) presented statistically significant expression (p < 0.05) when the different ACR grades were compared, and their expression levels changed proportionally to the severity of the rejection (Fig. 1C). Among them, 5 showed relevant diagnostic capacity with an AUC≥0.750 (Fig. 1D) and AUC>0.850 (Fig. 1E) for the detection of 1R and  $\geq 2R$  grades, respectively. Additionally, we observed high specificity and positive predictive values ( $\geq$ 83%) for these circulating lncRNAs (Table S2). Furthermore, to investigate whether circulating lncRNAs are independent predictors of grade≥2R ACR binary logistic regressions were performed. The best models were obtained for AL359220.1 and AC025279.1 (value of fold change≥1.5, optimum cut-off point obtained from the ROC curve) adjusted for age, sex and NT-proBNP levels. Specifically, AL359220.1 showed an odds ratio of 31.132 (95% CI 2.340–414.2, p < 0.01) with a C statistic of 0.939 (95% CI 0.848–1.000, *p*<0.0001), and AC025279.1 showed an odds ratio of 18.693 (95% CI 1.511–231.2, *p*<0.05) with a C statistic of 0.902 (95% CI 0.777–1.000, *p*<0.001).

The main function of lncRNAs is the regulation of gene expression through miRNA interactions [9]. Therefore, due to the current lack of knowledge of the specific biological functions of the described lncRNAs, we studied the possible function of lncRNAs as miRNA sponges in ACR. For this, we use our expression data set for miR-NAs and lncRNAs derived from ncRNA sequencing to obtain a thermodynamic measure of the lncRNA-miRNA interaction (Supplementary material). AC006525.1 and AC011455.8 showed a correlation>l0.60 L and a favourable interaction (minimum Gibbs free energy of -18 kcal/mol) with respect to randomness within the same RNA length for several miRNAs (Table 1). Then, a miRNA target prediction analysis was performed. Only experimentally validated miRNA targets previously published through reporter assays were included to ensure a high level of biological relevance (Table S3).

Nowadays, all commercial alternatives to EMB are restricted to reference commercial laboratories, such AlloMap [10] and percent donor-derived cell-free DNA (%ddcfDNA) [11]. Additionally, the costs of these tests are similar to that of EMB and not available in all countries [12]. For these reasons, although this is a pilot study with a small cohort and involving only a single center, our findings have provided substantial evidence and represent a necessary first step. Limiting factors could be addressed in future research, such as validation in a large multicenter cohort in which the response to the treatment will also be analyzed and the use of a simple standardized technique in all clinical laboratories for the identification of these potential lncRNAs as biomarkers of cardiac rejection.



**Fig. 1 A**. Schematic overview of identification strategy of candidate long non-coding RNAs (IncRNAs) for the detection of acute cellular rejection (ACR), both mild (1R) and moderate-severe ( $\ge 2R$ ) grades. FC, fold change. P adj, p adjusted. **B**. Hierarchical clustering shows a distinguishable lncRNA expression profiling among patient serum samples, visualized in a heatmap. Colors depict the relative expression level of each molecule, with blue being the lowest and yellow the highest. **C**. Dot plot graph of circulating expression levels of lncRNAs selected as potential biomarkers for the detection of acute cellular rejection (ACR). Comparison between the non-rejection group (grade 0R) and the different grades of acute rejection of heart allografts (ACR grade 1R and grade  $\ge 2R$ ), as well as between mild (1R) and moderate-severe ( $\ge 2R$ ) grades. Data are represented as the mean  $\pm$  SEM. A.u., arbitrary units. \*p < 0.05, \*\*\*p < 0.01, \*\*\*p < 0.001. **D**. Serum lncRNAs receiver operating characteristic curves for the detection of cardiac ACR of mild (1R) grade. AUC, area under the curve. **E**. Serum lncRNAs receiver operating characteristic curves for the detection of cardiac ACR of moderate-severe ( $\ge 2R$ ) grades. AUC, area under the curve

### Table 1 Significant IncRNA-miRNA interactions

IncRNA	miRNA	Size	kcal.mol	Predict	Fold Change
AC006525.1	miR-3605-3p	22	-21,11	-17,12715	-3,98285
	miR-3178	16	-19,06	-16,44425	-2,61575
AC011455.8	miR-3178	16	-18,32	-16,54603	-1,77397
	miR-3605-3p	22	-16,51	-13,99351	-2,51649
	miR-6787-5p	21	-18.07	-14,41893	-3.65107

AC006525.1 and AC011455.8 showed a correlation > 10.60 L and a favourable interaction (minimum Gibbs free energy of -18 kcal/mol) with respect to randomness within the same RNA length for these miRNAs.  $P \le 0.10$ 

#### Abbreviations

ACR	Acute cellular rejection
AUC	Area under the curve
EMB	Endomyocardial biopsies
FC	Fold change
ISHLT	International Society for Heart and Lung Transplantation
LncRNA	Long non-coding RNA
NT-proBNP	N-terminal pro–B-type natriuretic peptide
ROC	Receiver operating characteristic
%ddcfDNA	Percent donor-derived cell-free DNA

## **Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40364-024-00590-0.

Supplementary Material 1

### Acknowledgements

Not applicable.

#### Author contributions

Esther Roselló-Lletí conceived the original idea and supervised the project. Esther Roselló-Lletí, Manuel Portolés, and Estefanía Tarazón planned the experiments and study design. Ignacio Sánchez-Lázaro, and Luis Martínez-Dolz provided the samples. Lorena Pérez-Carrillo, and Isaac Giménez-Escamilla collected and processed the samples. Irene González-Torrent, Marta Delgado-Arija, Ignacio Sánchez-Lázaro, María García-Manzanares, Luis Martínez-Dolz, Manuel Portolés, Estefanía Tarazón, and Esther Roselló-Lletí contributed to data analysis and interpretation of results. Lorena Pérez-Carrillo wroet the main manuscript text. All authors contributed to the final version of the manuscript. Luis Martínez-Dolz, Estefanía Tarazón, and Esther Roselló-Lletí acquired funding for this study.

#### Funding

This work was supported by the National Institute of Health "Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III" (Projects: PI20/01469, PI20/00071 and PMPTA22/00184) co-funded by European Union; Miguel Servet contracts: CP18/00145 co-funded by European Union, European Social Fund (ESF) "The ESF invests in your future" and CP21/00041 co-funded by European Union; contracts FI21/00186 and FI21/00034]; "Consorcio Centro de Investigación Biomédica en Red" [CIBERCV, under Grant CB16/11/00261]; Ministry of Science and Innovation (MCIN, https://doi. org/10.13039/501100011033) and State Investigation Agency (AEI) (Project CNS2022-135769) co-funded by European Union "Next Generation EU" and the European Recovery, Transformation and Resilience Plan (PRTR); Conselleria de educación, universidades y empleo (Project CIAICO/2022/246, contract CIACIF/2022/429).

#### Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

## Declarations

#### Ethics approval and consent to participate

The study was carried out in accordance with the principles of the Declaration of Helsinki and the study was approved by the Ethics Committee (Biomedical Investigation Ethics Committee of University and Polytechnic Hospital La Fe of Valencia, Spain). Written informed consent was obtained and documented from all patients.

## **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

Received: 8 November 2023 / Accepted: 4 April 2024 Published online: 12 May 2024

#### References

- Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Hsich E, et al. The international thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report — 2019; focus theme: Donor and recipient size match. J Heart Lung Transpl. 2019;38:1056–66.
- Orrego CM, Cordero-Reyes AM, Estep JD, Loebe M, Torre-Amione G. Usefulness of routine surveillance endomyocardial biopsy 6 months after heart transplantation. J Heart Lung Transpl. 2012;31:845–9.
- Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 Working Formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transpl. 2005;24:1710–20.
- Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transpl. 2023;42:e1–141.
- Kennel PJ, Saha A, Maldonado DA, Givens R, Brunjes DL, Castillero E, et al. Serum exosomal protein profiling for the non-invasive detection of cardiac allograft rejection. J Heart Lung Transpl. 2018;37:409–17.
- Pérez-Carrillo L, Giménez-Escamilla I, Sánchez-Lázaro I, Triviño JC, Feijóo-Bandín S, Lago F, et al. Alpha-cardiac actin serum expression levels detect Acute Cellular rejection in Heart Transplant patients. Transplantation. 2023;107:466–74.
- Lu D, Thum T. RNA-based diagnostic and therapeutic strategies for cardiovascular disease. Nat Rev Cardiol. 2019;16:661–74.
- Lu J, Wang X, Zhang B, Li P, Du X, Qi F. The IncRNA PVT1 regulates autophagy in regulatory T cells to suppress heart transplant rejection in mice by targeting miR-146a. Cell Immunol. 2021;367:104400.
- 9. Das S, Shah R, Dimmeler S, Freedman JE, Holley C, Lee J-M, et al. Noncoding RNAs in Cardiovascular Disease: current knowledge, Tools and technologies for Investigation, and future directions: A Scientific Statement from the American Heart Association. Circ Genom Precis Med. 2020;13:e000062.
- Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, et al. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J. 2016;37:2591–601.
- Khush KK, Patel J, Pinney S, Kao A, Alharethi R, DePasquale E, et al. Noninvasive detection of graft injury after heart transplant using donor-derived cellfree DNA: a prospective multicenter study. Am J Transpl. 2019;19:2889–99.

12. Baran DA. Anything but a Biopsy: the Quest for Noninvasive Alternatives in Heart Transplantation. Transplantation. 2023;107:1875–6.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.